Another study conducted by Campani et al. [146] showed that a high score of the pre-treatment serum ALB–BIL grade combined with post-treatment serum AFP level change was independently correlated with worse OS and PFS in HCC patients receiving molecular targeted therapy with atezolizumab and bevacizumab. Here, AFP is linked to hepatocellular carcinoma.